Biotech Values

[DewDiligence]

Re: HCV programs that target NS5A

Other than the GNLB program that was just munched by GSK, there’s are two that I’m aware of:

1. The AZN program you mentioned that was acquired by way of Arrow Therapeutics in 2007 (#msg-16682361); and

2. The preclinical program that XTLB sold to Presidio Pharma for peanuts in early 2008 (#msg-27791536).

As I noted previously, AZN never talks about its NS5A program, which makes me wonder if it is still active.

If anyone knows of NS5A programs for HCV other than the ones cited here, please post.